Skip to content

Effect of Orka in Diabetes

The effects of Abelmoschus esculentus L pods on glycemic control and lipid profile in type II diabetic patients: Randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120112008712N2
Enrollment
80
Registered
2019-10-15
Start date
2019-09-23
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes Mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Type 2 diabetic patients who consume the hydroalcoholic extract of okra at a dose of 1000 mg three times daily after each meal for 90 days. Intervention 2: Control

Sponsors

Maragheh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients with at least 2 years of type 2 DM Using oral hypoglycemic agents but not insulin Fasting blood sugar (FBS) 150-200 mg/dl and HbA1c 7.5-9% Age between 40 and 60 years

Exclusion criteria

Exclusion criteria: unwillingness to participation; Pregnancy and lactation and in women of childbearing age without reliable contraceptive methods; Tobacco smokers and alcohol consumers and patients who tend to change their diet or exercise program. Any serious comorbidities (including renal failure, chronic hepatic failure, untreated heart failure, pulmonary infections and proliferative retinopathy), active neoplastic disease, a history of cancer less than 5 years, and depression

Design outcomes

Primary

MeasureTime frame
Fasting blood Suger. Timepoint: At the beginning and the end of study (60th day). Method of measurement: Lab Kit.;Lipid Profile. Timepoint: At the beginning and the end of study (60th day). Method of measurement: Lab Kit.

Secondary

MeasureTime frame
HOMA-IR. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: Lab Kit and Software calculation.;Hb A1C. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: Lab kit.;Body Mass Index. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: Scales and tape measure.;C reactive Protoein. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: lab kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Ziaee

Maragheh University of Medical Sciences

mjziaee@gmail.com+98 41 3725 6930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026